Human Kallikrein 13, His Tag (KL3-H5225) is expressed from human 293 cells (HEK293). It contains AA Gly 18 - Ile 262 (Accession # AAH69334).
Predicted N-terminus: Gly 18
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 28.0 kDa. The protein migrates as 33-40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 20 mM MES, 150 mM NaCl, pH6.0. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human Kallikrein 13, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Kallikrein-13 (KLK13) is also known as Kallikrein-like protein 4 (KLK-L4), is a secreted protein, belongs to the peptidase S1 family and Kallikrein subfamily. KLK-13 contains one peptidase S1 domain. KLK13 is mainly expressed in prostate, breast, testis and salivary gland. KLK13 may be involved in the pathogenesis and / or progression of breast and ovary cancers, and is regarded as a novel cancer biomarker. In addition, KLK13 interacts and forms complexes with several serum protease inhibitors, such as alpha2-macroglobulin, and its expression is regulated by steroid hormones.